02509

13.0106.87%
YW

Yiliang Wu

GM of Cellularforce & Executive Director

Mr. Yiliang Wu is GM of Cellularforce of Qyuns Therapeutics Co. Ltd. from December 2024 and has been its Executive Director since April 10, 2019. Mr. Wu was Executive Deputy GM of Cellularforce of Qyuns Therapeutics Co. Ltd. from March 23, 2023 to December 2024. Mr. Wu joined Qyuns Therapeutics Co., Ltd. and its subsidiaries in June 2015 and has been serving as the executive Deputy General Manager of Cellularforce since March 2023. Mr. Wu is experienced in biopharmaceutical industry, specialized in process development, quality control and commercial manufacturing of recombinant protein drugs. Mr. Wu joined Qyuns Therapeutics Co., Ltd. and its subsidiaries in June 2015 and served as the Director of Qyuns Therapeutics Co., Ltd.’s department of process research and development from June 2015 to January 2019. From February 2019 to February 2023, Mr. Wu served as the Chief Operating Officer of Qyuns Therapeutics Co., Ltd. During his tenure, we successfully completed pharmacology, preclinical pharmacology and toxicology studies for QX002N,QX005N, QX004N, QX006N and QX008N, which are currently in Phase I or II clinical research. Mr. Wu also served as the Vice President of production at Cellularforce from March 2019 to February 2023, where he was primarily responsible for the design, construction, testing and confirmation of manufacturing facilities and assisted in the establishment of quality management system. Prior to joining Qyuns Therapeutics Co., Ltd. and its subsidiaries, from July 2007 to March 2015, Mr. Wu worked at Hangzhou Genewave which is a subsidiary of Jiangsu T-mab. Mr. Wu successively served various positions at Jiangsu T-mab, including as: (i) a purification researcher in protein drug department from July 2008 to May 2010, where he was primarily responsible for the purification process development of two long-Acting recombinant cytokine-based drugs; and (ii) a deputy Manager of the antibody drugs department from May 2010 to May 2015, where he was involved in establishing the antibody drugs department and was responsible for its process research and pilot scale-up (500L scale) production system for antibody drugs. Mr. Wu graduated from Xiamen University in the PRC in July 2003 with a bachelor’s degree in biotechnology. He also obtained a master’s degree in cytobiology from Xiamen University in September 2006. He was certified as a senior engineer by Human Resources and Social Security Department of Jiangsu Province in December 2013.

Positions